Literature DB >> 10209513

An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model.

E D Williamson1, P M Vesey, K J Gillhespy, S M Eley, M Green, R W Titball.   

Abstract

The objective of this study was to identify an immunological correlate of protection for a two-component subunit vaccine for plague, using a mouse model. The components of the vaccine are the F1 and V antigens of the plague-causing organism, Yersinia pestis, which are coadsorbed to alhydrogel and administered intramuscularly. The optimum molar ratio of the subunits was determined by keeping the dose-level of either subunit constant whilst varying the other and observing the effect on specific antibody titre. A two-fold molar excess of F1 to V, achieved by immunizing with 10 micrograms of each antigen, resulted in optimum antibody titres. The dose of vaccine required to protect against an upper and lower subcutaneous challenge with Y. pestis was determined by administering doses in the range 10 micrograms F1 + 10 micrograms V to 0.01 microgram F1 + 0.01 microgram V in a two-dose regimen. For animals immunized at the 1-microgram dose level or higher with F1 + V, an increase in specific IgG1 titre was observed over the 8 months post-boost and they were fully protected against a subcutaneous challenge with 10(5) colony-forming units (CFU) virulent Y. pestis at this time point. However, immunization with 5 micrograms or more of each subunit was required to achieve protection against challenge with 10(7) CFU Y. pestis. A new finding of this study is that the combined titre of the IgG1 subclass, developed to F1 plus V, correlated significantly (P < 0.05) with protection. The titres of IgG1 in vaccinated mice which correlated with 90%, 50% and 10% protection have been determined and provide a useful model to predict vaccine efficacy in man.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10209513      PMCID: PMC1905224          DOI: 10.1046/j.1365-2249.1999.00859.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  14 in total

1.  Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge.

Authors:  G P Andrews; D G Heath; G W Anderson; S L Welkos; A M Friedlander
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

2.  Local and systemic immune response to a microencapsulated sub-unit vaccine for plague.

Authors:  E D Williamson; G J Sharp; S M Eley; P M Vesey; T C Pepper; R W Titball; H O Alpar
Journal:  Vaccine       Date:  1996-12       Impact factor: 3.641

3.  Plague immunization. II. Relation of adverse clinical reactions to multiple immunizations with killed vaccine.

Authors:  J D Marshall; P J Bartelloni; D C Cavanaugh; P J Kadull; K F Meyer
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

4.  Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis.

Authors:  G W Anderson; S E Leary; E D Williamson; R W Titball; S L Welkos; P L Worsham; A M Friedlander
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

Review 5.  Yersinia pestis--etiologic agent of plague.

Authors:  R D Perry; J D Fetherston
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

6.  The SCID/Beige mouse as a model to investigate protection against Yersinia pestis.

Authors:  M Green; D Rogers; P Russell; A J Stagg; D L Bell; S M Eley; R W Titball; E D Williamson
Journal:  FEMS Immunol Med Microbiol       Date:  1999-02

7.  Effectiveness of live or killed plague vaccines in man.

Authors:  K F Meyer
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

8.  A comparison of Plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model.

Authors:  P Russell; S M Eley; S E Hibbs; R J Manchee; A J Stagg; R W Titball
Journal:  Vaccine       Date:  1995-11       Impact factor: 3.641

9.  Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague.

Authors:  S E Leary; E D Williamson; K F Griffin; P Russell; S M Eley; R W Titball
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

10.  Differential regulation of IgG1 and IgE synthesis by interleukin 4.

Authors:  C M Snapper; F D Finkelman; W E Paul
Journal:  J Exp Med       Date:  1988-01-01       Impact factor: 14.307

View more
  52 in total

1.  Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis.

Authors:  Jim Hill; Catherine Copse; Sophie Leary; Anthony J Stagg; E Diane Williamson; Richard W Titball
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

2.  Development of a vaccinia virus based reservoir-targeted vaccine against Yersinia pestis.

Authors:  Debaditya Bhattacharya; Joan Mecsas; Linden T Hu
Journal:  Vaccine       Date:  2010-09-25       Impact factor: 3.641

3.  Evaluation of combinatorial vaccines against anthrax and plague in a murine model.

Authors:  Amanda B DuBois; Lucy C Freytag; John D Clements
Journal:  Vaccine       Date:  2007-04-20       Impact factor: 3.641

Review 4.  Interaction between Yersinia pestis and the host immune system.

Authors:  Bei Li; Ruifu Yang
Journal:  Infect Immun       Date:  2008-02-04       Impact factor: 3.441

5.  A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague.

Authors:  Hitoki Yamanaka; Teri Hoyt; Xinghong Yang; Sarah Golden; Catharine M Bosio; Kathryn Crist; Todd Becker; Massimo Maddaloni; David W Pascual
Journal:  Infect Immun       Date:  2008-08-11       Impact factor: 3.441

6.  Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.

Authors:  Danielle A Wagner; Sean M Kelly; Andrew C Petersen; Nathan Peroutka-Bigus; Ross J Darling; Bryan H Bellaire; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2019-10-11       Impact factor: 8.947

7.  Yersinia pestis IS1541 transposition provides for escape from plague immunity.

Authors:  Claire A Cornelius; Lauriane E Quenee; Derek Elli; Nancy A Ciletti; Olaf Schneewind
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

8.  An IL-12 DNA vaccine co-expressing Yersinia pestis antigens protects against pneumonic plague.

Authors:  Hitoki Yamanaka; Teri Hoyt; Richard Bowen; Xinghong Yang; Kathryn Crist; Sarah Golden; Massimo Maddaloni; David W Pascual
Journal:  Vaccine       Date:  2008-10-26       Impact factor: 3.641

9.  An age-old paradigm challenged: old baboons generate vigorous humoral immune responses to LcrV, a plague antigen.

Authors:  Sue Stacy; Amanda Pasquali; Valerie L Sexton; Angelene M Cantwell; Ellen Kraig; Peter H Dube
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

10.  Different pathologies but equal levels of responsiveness to the recombinant F1 and V antigen vaccine and ciprofloxacin in a murine model of plague caused by small- and large-particle aerosols.

Authors:  Richard J Thomas; Daniel Webber; Aaron Collinge; Anthony J Stagg; Stephen C Bailey; Alejandro Nunez; Amanda Gates; Pramukh N Jayasekera; Rosa R Taylor; Steve Eley; Richard W Titball
Journal:  Infect Immun       Date:  2009-02-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.